Gastrin-releasing peptide receptor-targeted gadolinium oxide-based multifunctional nanoparticles for dual magnetic resonance/fluorescent molecular imaging of prostate cancer

Cui, Danting; Lü, Xiaodan; Yan, Changqing; Liu, Xiang; Hou, Meirong; Qi, Xia; Xu, Yikai; Liu, Ruiyuan

doi:10.2147/ijn.s139246

Cited by 14 publications

(14 citation statements)

References 26 publications

(27 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Gadolinium oxide [4,5], gadolinium fluoride [6,7] and gadolinium phosphate [8] NPs have been synthesised and tried as T 1 contrast agents. Most recent examples are focused on targeted T 1 Gd 2 O 3 NPs [9], dual T 1 -T 2 MRI probes [10], hybrid MRI/fluorescent probes [11,12] and theranostic (theraphy + diagnostic) probes [13] for tumour imaging. A Gd 2 O 3 -NP hybrid CT/MRI probe functionalised with bisphosphonate was used by Mastrogiacomo et al to visualise calcium phosphate bone cement [14].…”

Section: Paramagnetic Gd 2 O 3 Nanoparticlesmentioning

confidence: 99%

Iron Oxide Nanoparticles: An Alternative for Positive Contrast in Magnetic Resonance Imaging

et al. 2020

View full text Add to dashboard Cite

Iron oxide nanoparticles have been extensively utilised as negative (T2) contrast agents in magnetic resonance imaging. In the past few years, researchers have also exploited their application as positive (T1) contrast agents to overcome the limitation of traditional Gd3+ contrast agents. To provide T1 contrast, these particles must present certain physicochemical properties with control over the size, morphology and surface of the particles. In this review, we summarise the reported T1 iron oxide nanoparticles and critically revise their properties, synthetic protocols and application, not only in MRI but also in multimodal imaging. In addition, we briefly summarise the most important nanoparticulate Gd and Mn agents to evaluate whether T1 iron oxide nanoparticles can reach Gd/Mn contrast capabilities.

show abstract

Section: Paramagnetic Gd 2 O 3 Nanoparticlesmentioning

confidence: 99%

Iron Oxide Nanoparticles: An Alternative for Positive Contrast in Magnetic Resonance Imaging

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Simultaneous optical and MR imaging of cancers was recently investigated by labeling recombinant humanized monoclonal antibodies or high-affinity small peptides against tumor receptors, which serve as targeting ligands, with near infrared dyes, and conjugating them to MNPs for simultaneous optical and MR imaging of cancers (Lin et al, 2018 ). Additionally, peptide-modified gadolinium oxide nanoprobes containing fluorescein for targeted MR/optical dual-modality imaging of various cancers have been engineered (Cui et al, 2017 ). Live-cell imaging studies suggest that amphiphilic dual-modality nanoprobes, containing a fluorophore for optical imaging and a metal ion chelator complexed with Gd for MRI, can self-assemble into supramolecular nanostructures and effectively label cells (Liu et al, 2015 ).…”

Section: Introductionmentioning

confidence: 99%

A Novel Metal-Based Imaging Probe for Targeted Dual-Modality SPECT/MR Imaging of Angiogenesis

et al. 2018

View full text Add to dashboard Cite

Superparamagnetic iron oxide nanoparticles with well-integrated multimodality imaging properties have generated increasing research interest in the past decade, especially when it comes to the targeted imaging of tumors. Bevacizumab (BCZM) on the other hand is a well-known and widely applied monoclonal antibody recognizing VEGF-A, which is overexpressed in angiogenesis. The aim of this proof-of-concept study was to develop a dual-modality nanoplatform for in vivo targeted single photon computed emission tomography (SPECT) and magnetic resonance imaging (MRI) of tumor vascularization. Iron oxide nanoparticles (IONPs) have been coated with dimercaptosuccinic acid (DMSA), for consequent functionalization with the monoclonal antibody BCZM radiolabeled with 99mTc, via well-developed surface engineering. The IONPs were characterized based on their size distribution, hydrodynamic diameter and magnetic properties. In vitro cytotoxicity studies showed that our nanoconstruct does not cause toxic effects in normal and cancer cells. Fe3O4-DMSA-SMCC-BCZM-99mTc were successfully prepared at high radiochemical purity (>92%) and their stability in human serum and in PBS were demonstrated. In vitro cell binding studies showed the ability of the Fe3O4-DMSA-SMCC-BCZM-99mTc to bind to the VEGF-165 isoform overexpressed on M-165 tumor cells. The ex vivo biodistribution studies in M165 tumor-bearing SCID mice showed high uptake in liver, spleen, kidney and lungs. The Fe3O4-DMSA-SMCC-BCZM-99mTc demonstrated quick tumor accumulation starting at 8.9 ± 1.88%ID/g at 2 h p.i., slightly increasing at 4 h p.i. (16.21 ± 2.56%ID/g) and then decreasing at 24 h p.i. (6.01 ± 1.69%ID/g). The tumor-to-blood ratio reached a maximum at 24 h p.i. (~7), which is also the case for the tumor-to-muscle ratio (~18). Initial pilot imaging studies on an experimental gamma-camera and a clinical MR camera prove our hypothesis and demonstrate the potential of Fe3O4-DMSA-SMCC-BCZM-99mTc for targeted dual-modality imaging. Our findings indicate that Fe3O4-DMSA-SMCC-BCZM-99mTc IONPs could serve as an important diagnostic tool for biomedical imaging as well as a promising candidate for future theranostic applications in cancer.

show abstract

“…Apart from iron oxide nanoparticles several other metal oxide nanoparticles have been constructed and used for imaging, and drug delivery applications [165, 189–191]. However, their use is often limited due to the accumulation of metal in the body after drug administration causing toxicity.…”

Section: Nanomaterials As Drug Delivery Agentsmentioning

confidence: 99%

Current trends and challenges in cancer management and therapy using designer nanomaterials

Navya¹,

et al. 2019

View full text Add to dashboard Cite

Nanotechnology has the potential to circumvent several drawbacks of conventional therapeutic formulations. In fact, significant strides have been made towards the application of engineered nanomaterials for the treatment of cancer with high specificity, sensitivity and efficacy. Tailor-made nanomaterials functionalized with specific ligands can target cancer cells in a predictable manner and deliver encapsulated payloads effectively. Moreover, nanomaterials can also be designed for increased drug loading, improved half-life in the body, controlled release, and selective distribution by modifying their composition, size, morphology, and surface chemistry. To date, polymeric nanomaterials, metallic nanoparticles, carbon-based materials, liposomes, and dendrimers have been developed as smart drug delivery systems for cancer treatment, demonstrating enhanced pharmacokinetic and pharmacodynamic profiles over conventional formulations due to their nanoscale size and unique physicochemical characteristics. The data present in the literature suggest that nanotechnology will provide next-generation platforms for cancer management and anticancer therapy. Therefore, in this critical review, we summarize a range of nanomaterials which are currently being employed for anticancer therapies and discuss the fundamental role of their physicochemical properties in cancer management. We further elaborate on the topical progress made to date toward nanomaterial engineering for cancer therapy, including current strategies for drug targeting and release for efficient cancer administration. We also discuss issues of nanotoxicity, which is an often-neglected feature of nanotechnology. Finally, we attempt to summarize the current challenges in nanotherapeutics and provide an outlook on the future of this important field.

show abstract

Gastrin-releasing peptide receptor-targeted gadolinium oxide-based multifunctional nanoparticles for dual magnetic resonance/fluorescent molecular imaging of prostate cancer

Cited by 14 publications

References 26 publications

Iron Oxide Nanoparticles: An Alternative for Positive Contrast in Magnetic Resonance Imaging

Iron Oxide Nanoparticles: An Alternative for Positive Contrast in Magnetic Resonance Imaging

A Novel Metal-Based Imaging Probe for Targeted Dual-Modality SPECT/MR Imaging of Angiogenesis

Current trends and challenges in cancer management and therapy using designer nanomaterials

Contact Info

Product

Resources

About